Although mast cell functions have classically been related to allergic responses [1] [2] [3] , recent studies indicate that these cells contribute to other common diseases such as multiple sclerosis, rheumatoid arthritis, atherosclerosis, aortic aneurysm and cancer [4] [5] [6] [7] [8] . This study presents evidence that mast cells also contribute to diet-induced obesity and diabetes. For example, white adipose tissue (WAT) from obese humans and mice contain more mast cells than WAT from their lean counterparts. Furthermore, in the context of mice on a Western diet, genetically induced deficiency of mast cells, or their pharmacological stabilization, reduces body weight gain and levels of inflammatory cytokines, chemokines and proteases in serum and WAT, in concert with improved glucose homeostasis and energy expenditure. Mechanistic studies reveal that mast cells contribute to WAT and muscle angiogenesis and associated cell apoptosis and cathepsin activity. Adoptive transfer experiments of cytokine-deficient mast cells show that these cells, by producing interleukin-6 (IL-6) and interferon-c (IFN-c), contribute to mouse adipose tissue cysteine protease cathepsin expression, apoptosis and angiogenesis, thereby promoting diet-induced obesity and glucose intolerance. Our results showing reduced obesity and diabetes in mice treated with clinically available mast cell-stabilizing agents suggest the potential of developing new therapies for these common human metabolic disorders.
In addition to adipocytes, it has been shown that WAT in obese humans and mice contains macrophages and lymphocytes [9] [10] [11] . As expected from these previous studies, we found that WAT from obese subjects displayed more staining by the macrophage-specific monoclonal antibody HAM56 (cell numbers per mm 2 ) than those from lean donors ( Fig. 1a) , with some of these stained macrophages bordering microvessels (Fig. 1b) . These inflammatory cells furnish cytokines, growth factors, chemokines and proteases in WAT 11, 12 . However, the role of these cells in the pathogenesis of obesity and its associated metabolic complications remains uncertain. Other heretofore underrecognized cells may also be crucial contributors. Like macrophages or lymphocytes, mast cells are also inflammatory cells. Staining WAT sections with a mast cell tryptase monoclonal antibody revealed higher numbers of mast cells in WAT from obese subjects compared with that from lean donors ( Fig. 1c-e ). Like macrophages, many of these mast cells adjoin microvessels ( Fig. 1c,d) , although WAT had significantly fewer mast cells than macrophages (Fig. 1e) . This increased mast cell content of WAT from obese subjects suggests increased systemic mast cell protease levels. Obese subjects (body mass index Z 32 kg mm À2 ) had significantly higher serum tryptase concentrations than lean individuals (body mass index o 26 kg per mm 2 ) before (P ¼ 0.01) and after adjusting for gender (P ¼ 0.01, multivariate analysis) ( Fig. 1f) . These observations suggest an association between mast cells and obesity.
To assess direct participation of mast cells in obesity, we studied diet-induced obesity in mast cell-deficient Kit W-sh/W-sh mice, which lack mature mast cells owing to an inversion mutation of the promoter region of the gene encoding c-Kit 13 , a growth factor receptor required for mast cell differentiation and survival. Six-week-old male ( Fig. 2a ) and female ( Supplementary Fig. 1a ) Kit W-sh/W-sh mice fed a Western diet for 12 weeks gained significantly less body weight than wild-type (WT) congenic controls. Similarly, WT mice receiving a daily intraperitoneal (i.p.) injection of the mast cell stabilizer disodium cromoglycate (DSCG) [14] [15] [16] also had attenuated body weight gain ( Fig. 2a ). DSCG treatment did not further affect the body weight of the Kit W-sh/W-sh mice, suggesting it acted through mast cells. Consistent with their lower body weight, both male and female Kit W-sh/W-sh mice or those receiving DSCG had significantly less total subcutaneous and visceral fat than untreated WT controls ( Fig. 2a and Supplementary Fig. 1a ).
Earlier studies revealed normal numbers and activities of monocytes or macrophages and neutrophils in WT and Kit W-sh/W-sh mice 6, 7, 17 . Using T or B lymphocytes from Kit W-sh/W-sh mice, we detected no significant activity differences in a mixed lymphocyte reaction assay compared to WT mice (data not shown). Whereas Western diet-fed WT mouse livers were steatotic with abundant c-Kit CD117 + mast cells, those from Kit W-sh/W-sh or WT mice treated with DSCG under the same dietary conditions did not contain mast cells and had a similar histological appearance to chow diet-fed WT mice (Supplementary Fig. 1b ). Histological analysis of the intestine, colon, stomach and pancreas also did not reveal obvious phenotypic differences between chow diet-fed WT mice and Kit W-sh/W-sh or DSCG-treated WT mice fed any of the dietary regimens (data not shown). Body composition analysis revealed a lower fat mass but a higher lean mass in Kit W-sh/W-sh mice or both WT and Kit W-sh/W-sh mice that received DSCG as compared to WT mice that did not receive DSCG after 12 weeks of a Western diet ( Supplementary  Fig. 1c ). From the data presented so far, it seems that the reduced obesity in Kit W-sh/W-sh or DSCG-treated mice resulted from a loss of mast cell function rather than from a confounding general health issue.
Similar to the results in human WAT ( Fig. 1c-e ), immunostaining with a monoclonal antibody to CD117 detected significantly more mast cells in WAT from obese mice fed a Western diet than in WAT from lean mice fed a chow diet, with many of these mast cells located near microvessels ( Fig. 2b,c) . Notably, DSCG treatment did not significantly reduce WAT mast cell content in Western diet-fed WT mice (Fig. 2b,c ), but these mice responded similarly to Kit W-sh/W-sh mice in body weight gain, suggesting that DSCG inactivated mast cells but did not affect their recruitment to the WAT. In contrast, immunostaining with a Mac-2-specific monoclonal antibody detected significantly fewer macrophages in Kit W-sh/W-sh and DSCG-treated mice than in untreated Western diet-fed WT mice ( Fig. 2d ). High mast cell numbers but low macrophage numbers in WAT from DSCG-treated, Western diet-fed WT mice suggest that mast cells appear in WAT before macrophages, a hypothesis that merits further examination.
Along with lower body weight, male and female Kit W-sh/W-sh mice or those receiving DSCG also had significantly lower concentrations of serum leptin than WT controls ( Supplementary Fig. 1d ). Glucose tolerance assays ( Fig. 2e ) and insulin sensitivity assays (Supplementary Fig. 1e ) in Western diet-fed mice revealed significantly higher glucose tolerance and insulin sensitivity of Kit W-sh/W-sh mice or WT mice receiving DSCG than WT control mice. These mice also had lower serum insulin concentrations than the WT control mice ( Supplementary Fig. 1f ).
To understand the mechanisms of these salutary effects of mast cell deficiency or inactivation, we performed energy expenditure assays and measured brown fat uncoupled protein-1 (UCP-1), a marker of energy expenditure 18, 19 . When we measured food and water intake, fecal and urine production and O 2 consumption and CO 2 production, we found that Kit W-sh/W-sh mice and DSCGtreated WT mice had a higher resting metabolic rate, illustrated by significantly more O 2 consumption and CO 2 production than untreated WT mice ( Supplementary Table 1 ). These mice had higher expression of UCP-1 in their brown fat, as compared to WT control mice ( Fig. 2f) .
To test whether DSCG also reverses preestablished obesity and diabetes, we fed WT mice a Western diet for 12 weeks to produce obesity and diabetes and grouped these obese and diabetic mice into four treatment groups: group 1, continued on a Western diet; group 2, switched to a chow diet; group 3, continued on a Western diet but with a daily i.p. injection of DSCG; and group 4, switched to a chow diet and treated with DSCG. Although changing the diet (group 2) also reduced body weight (8%) and improved glucose tolerance as expected, combined diet change and DSCG administration (group 4) yielded the greatest improvement of both body weight and glucose tolerance ( Fig. 2g ). Eight weeks after DSCG treatment, the body weight of group 3 mice decreased by 12%, but that of group 4 mice decreased by 19% and stabilized around 40-41 g, with these mice showing the highest glucose tolerance among the four groups ( Fig. 2g ), suggesting the possibility of managing preexisting obesity and diabetes by stabilizing mast cells. Use of a second mast cell stabilizer, ketotifen 20, 21 , confirmed this hypothesis. Like DSCG treatment, daily i.p. injection of ketotifen lowered diet-induced body weight gain and enhanced glucose tolerance ( Fig. 2h ). As we anticipated, ketotifen also improved preestablished obesity and diabetes in mice that had consumed a Western diet for 12 weeks (Fig. 2i) .
To affirm that the phenotypes we observed from the Kit W-sh/W-sh mice or those receiving DSCG or ketotifen stemmed from the loss of mast cell functions, we used Kit W/Wv mice as an additional model of genetically induced mast cell deficiency 22 . Kit W/Wv mice carry a compound mutation (one impaired allele and the other null) of the Kit gene. Whereas WT mice (WBB6F1/J background) continued gaining body weight and developed glucose intolerance on a Western diet, Kit W/Wv mice and those receiving DSCG or ketotifen showed a smaller body weight gain and higher glucose tolerance (Fig. 2j) . These observations provided further support for the direct participation of mast cells in both obesity and diabetes.
The development of obesity involves extracellular matrix remodeling and angiogenesis 23 . Inhibition of angiogenesis blocks adipose tissue 
development in mice 24 . Besides supplying the WAT with nutrients, microvessels provide a path for leukocyte infiltration followed by adipokine release 25, 26 . The appearance of macrophages and mast cells next to the microvessels in WAT ( Fig. 1b,d ) supported this hypothesis. Furthermore, we found substantial immunostaining of CD31 along endothelial cells in WAT and muscle tissue from obese WT mice ( Fig. 3a,b) . In contrast, Western diet-fed Kit W-sh/W-sh mice or those receiving DSCG had CD31 + areas similar to those from chow diet-fed lean mice ( Fig. 3a,b ). Reduced angiogenesis should limit nutrient supply, impairing cell viability 24, 27 . Thus, we performed TUNEL staining and found higher numbers of apoptotic cells in WAT from Kit W-sh/W-sh mice or those receiving DSCG compared with WT controls (Fig. 3c) . Reduced angiogenesis may also impair leukocyte infiltration ( Fig. 2d ) and therefore reduce WAT production of inflammatory mediators 28 . Consistent with this notion, Kit W-sh/W-sh mice or those receiving DSCG had lower concentrations of IL-6, tumor necrosis factor-a (TNF-a), IFN-g, monocyte chemoattractant protein-1, matrix metalloprotease-9 and cathepsin S in serum and WAT, although some adipokines and proteases (for example, adiponectin and cathepsin L) did not change significantly ( Supplementary Table 2 ). Extracellular matrix proteolysis contributes to angiogenesis by releasing proangiogenic peptides 29 . We have previously shown that cathepsin S has a crucial role in angiogenesis by degrading antiangiogenic peptides and generating proangiogenic lamin-5 fragment g2 (ref. 30 ). The lower angiogenesis in Kit W-sh/W-sh and DSCG-treated mice (Fig. 3a,b ) accompanied low cathepsin S amounts in WAT and serum ( Fig. 3d-f ). After incubating WAT protein extracts with [ 125 I]-JPM, a cysteine protease inhibitor E64 derivative that selectively labels active cathepsins 31 , we found smaller active cathepsin B, cathepsin S, and cathepsin L amounts in Kit W-sh/W-sh mice than in WT mice ( Fig. 3d) . Notably, WAT from DSCG-treated mice had levels of active cathepsins similar to WT controls, consistent with our observation of large numbers of mast cells in these tissues ( Figs. 2c and 3d) . Cathepsin S ELISA allowed us to quantify local and systemic levels among different mice. Similar to our observations from the JPM labeling experiment, both male and female Kit W-sh/W-sh mice showed lower serum and WAT cathepsin S concentrations than the WT controls ( Fig. 3e) . In contrast, DSCG treatment significantly reduced the cathepsin S amounts in serum but not in WAT extracts (Fig. 3f ), suggesting that DSCG effectively stabilized mast cells in vivo. We wanted to further substantiate our hypothesis that the improvement in Kit W-sh/W-sh mice of experimentally induced metabolic disorders result from the loss of mast cells, rather than from a generalized illness that may cause them to eat less or alter their glucose homeostasis. Thus, we reconstituted Kit W-sh/W-sh mice with bone marrow-derived mast cells (BMMCs) prepared in vitro from WT mice and mice lacking the three common mast cell cytokines IL-6, TNF-a and IFN-g, which are known stimulators of vascular cell cathepsin activity 6, 7 . After 13 weeks on a Western diet, mice reconstituted with WT and Tnf À/À BMMCs but not Il6 À/À and Ifng À/À BMMCs gained significantly more body weight than nonreconstituted mice, although they remained leaner than WT controls (Fig. 4a) . Consistent with the body weight differences, those receiving WT and Tnf À/À BMMCs had significantly higher serum leptin, insulin and glucose concentrations than nonreconstituted mice or those receiving Il6 À/À and Ifng À/À BMMCs (Fig. 4b-d ). Kit W-sh/W-sh mice receiving Il6 À/À and Ifng À/À BMMCs but not WT or Tnf À/À BMMC also showed improved glucose tolerance (Fig. 4e) , suggesting that mast cell-derived IL-6 and IFN-g contribute to these metabolic derangements. Although we found smaller WAT adipocytes in Kit W-sh/W-sh mice compared to WT controls, WAT adipocyte size did not vary significantly between the various BMMC-reconstituted mice (data not shown). Notably, WAT from the various BMMCreconstituted Kit W-sh/W-sh mice had similar numbers of mast cells between the groups but fewer than those in WT mice (Fig. 4f) , which could explain the incomplete restoration of body weight gain and serum levels of leptin, insulin and glucose ( Fig. 4a-d) . Along with increased body weight gain, reconstitution of WT BMMCs also lowered brown fat UCP-1 levels in Kit W-sh/W-sh mice (Fig. 4g) , affirming a key role of mast cells in energy expenditure.
As discussed, mast cells may contribute to obesity by stimulating WAT protease expression, thereby promoting microvessel growth. The body weight recovery in Kit W-sh/W-sh mice after engraftment of WT BMMCs and Tnf À/À BMMCs but not Il6 À/À or Ifng À/À BMMCs suggests a role for mast cell-derived IL-6 and IFN-g in WAT protease expression and the associated angiogenesis. To test this hypothesis, we incubated mouse 3T3-L1 preadipocytes with degranulated BMMC extract (Fig. 4h) or live BMMCs (data not shown) and found that both WT and Tnf À/À BMMCs but not Il6 À/À or Ifng À/À BMMCs increased adipocyte cathepsin activities in a JPM-labeling assay. Indeed, reconstitution of WT and Tnf À/À BMMCs but not Il6 À/À or Ifng À/À BMMCs in Kit W-sh/W-sh mice resulted in higher WAT cathepsin activities (Fig. 4i) . Consistent with our hypothesis, both WAT and muscle from Kit W-sh/W-sh mice receiving WT and Tnf À/À BMMCs but not Il6 À/À or Ifng À/À BMMCs had partially preserved CD31 + areas (Fig. 4j) . Although other mechanisms may be at play in this process, mast cell-mediated protease expression and associated angiogenesis may favor WAT growth.
This study establishes a previously undescribed role of mast cells in mouse obesity and diabetes and suggests a potential new therapeutic approach for these common human metabolic diseases.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
ONLINE METHODS
Mice. We purchased WT (C57BL/6 and WBB6F1/J), Il6 À/À (C57BL/6, N11), Ifng À/À (C57BL/6, N10) and Kit W/Wv (WBB6F1/J) mice from the Jackson Laboratories. We generated congenic Tnf À/À (C56BL/6, N10) and Kit W-sh/W-sh (C57BL/6, N10) mice as previously described 6, 32 . The Harvard Medical School Standing Committee on Animals approved all mouse protocols. To induce obesity, we fed 6-week-old mice (females and males) a Western diet containing 22.6% protein, 45.2% carbohydrate, 20.1% fat, and 1.25% cholesterol (Research Diet) for 12-13 weeks. We monitored body weight weekly. At the end of each course of Western diet consumption, we performed glucose tolerance, insulin tolerance and energy expenditure assays, and we determined body lean and fat mass as previously described 33, 34 . We collected mouse blood samples for serum adipokine measurement. We collected subcutaneous, visceral, and brown fat and skeletal muscle for protein extraction and paraffin section preparation. We used tissue protein extracts for ELISA, immunoblot analysis and cathepsin active site JPM labeling. For immunoblots, we used 30 mg of proteins to detect UCP-1 (1 in 3,000 antibody dilution, Abcam), actin (1 in 500 antibody dilution, Abcam) or glyceraldehyde-3-phosphate dehydrogenase (1 in 1,000 antibody dilution, Santa Cruz). We labeled the cathepsin active site as previously described 31, 33 . We collected the liver and gastrointestinal tract for histological analysis.
Human subject selection. In this study, we enrolled 80 obese subjects that had been prospectively recruited between 2003 and 2007 at the Department of Nutrition of Hôtel-Dieu Hospital, Paris, France. Detailed clinical and biological parameters are listed in Supplementary Table 3 . These subjects were candidates for either a dietary intervention or gastric surgery in a clinical investigation program. We excluded those with evidence of inflammatory or infectious diseases, cancer, alcohol abuse or kidney disease. At the time of gastric surgery, we obtained subcutaneous adipose tissue from the periumbilical area in a subset of the obese subjects (n ¼ 12, Supplementary Table 4 ). We recruited healthy, nonobese, age-matched (P ¼ 0.11) individuals (n ¼ 32) living in the same geographic area as controls ( Supplementary Table 3 ). In ten lean controls ( Supplementary Table 4 ), we obtained subcutaneous adipose tissue in the periumbilical area by needle biopsy. We determined serum insulin concentrations with an IRMA kit (CisBio International). We evaluated insulin sensitivity by the quantitative insulin sensitivity check index (QUICKI) ¼ 1 / [log fasting insulin (mM) + log fasting glycemia (mg dl À1 )]. We processed all tissue samples under the same conditions. The Ethics Committee of the Hôtel-Dieu Hospital approved the clinical investigations, and all subjects gave written informed consent.
Immunohistology. We used antibodies to human HAM56 (1 in 100, Dako), human tryptase (1 in 100, Dako), mouse Mac-2 (1 in 25,000, Cedarlane), mouse CD117 (1 in 10, eBiosciences) and mouse CD31 (1 in 400, Pharmingen) to immunostain for macrophages, mast cells and microvessels on WAT, muscle and liver paraffin sections. Researchers blinded to the origin of tissue counted the total human HAM56 + macrophages, human tryptase + and mouse CD117 + mast cells on each section, and data are presented as cell numbers per mm 2 . We determined CD31 + areas in WAT and muscle with Image-Pro Plus software as described 30, 35 . H&E staining assisted histological assessment of the gastrointestinal tract.
Enzyme-linked immunosorbent assay. We pulverized frozen mouse WAT and lysed it in RIPA buffer (Pierce). We subjected both WAT and serum samples to ELISA analysis for IL-6 (BD Biosciences), TNF-a, IFN-g, monocyte chemoattractant protein-1 (PeproTech), adiponectin, matrix metalloprotease-9, cathepsin S (R&D Systems) and cathepsin L (Bender MedSystems), according to the manufacturers' instructions.
To measure human serum tryptase abundance, we precoated a 96-well plate with a polyclonal antibody to human tryptase (1 in 1,000, Calbiochem). We added human serum samples (1:1 diluted in 1Â PBS) along with recombinant human tryptase as a standard to the antibody-coated plate. After a 2-h incubation at 25 1C, we washed the plate and incubated it for 1 h with a monoclonal antibody to human tryptase (1 in 2,000, AbD Serotec). We used horseradish peroxidase-conjugated antibody to mouse IgG (1 in 1,000, Thermo Scientific) as the detecting antibody.
Cell culture. We prepared BMMCs and performed reconstitution experiments in 6-week-old male Kit W-sh/W-sh mice as we reported previously 6, 7 . Two weeks after BMMC reconstitution, we gave the mice a Western diet. We recorded mouse body weight weekly and performed the glucose tolerance assay before harvesting the WAT.
To assess the role of mast cells in 3T3-L1 cell cathepsin expression, we added either live BMMCs (2,000,000 cells per well for six-well plate) or their degranulated protein extract (equivalent to the live cell numbers) into 100% confluent 3T3-L1 cells. We maintained the co-cultures for 7-9 d, and we replaced culture medium with live BMMCs or BMMC protein extracts every 2 d. We then used 3T3-L1 cells for cathepsin active site labeling as previously described 31 .
Statistical analyses. All data from mice are expressed as means ± s.e.m., and we determined statistical significance with a nonparametric Mann-Whitney test, owing to our small data size and abnormal data distribution. Human serum tryptase ELISA data are expressed as means ± s.e.m. We used Student's t test, analysis of variance and Chi-square test for noncontinuous values for comparisons between groups. We used standard least squares regression method for multivariate analysis. We considered P o 0.05 statistically significant.
